82 related articles for article (PubMed ID: 10560396)
1. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
Mohri N; Mizuno I; Akamo Y; Takeyama H; Manabe T
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1791-3. PubMed ID: 10560396
[TBL] [Abstract][Full Text] [Related]
2. Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.
Takeyama H; Mohri N; Mizuno I; Akamo Y; Sawai H; Manabe T; Yotsuyanagi T; Nakamura S
Anticancer Res; 2006; 26(6B):4603-6. PubMed ID: 17201184
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis].
Mizuno I; Yasui T; Takeyama H; Ishikawa M; Terada J; Mohri N; Ueda T; Sumita N; Kobayashi K; Akamo Y
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1598-601. PubMed ID: 7574769
[TBL] [Abstract][Full Text] [Related]
4. [Intraperitoneal administration of carboplatin loaded alpha-tricalcium phosphate (alpha-TCP) particles in rats bearing abdominal carcinomatosis].
Ueda T; Mizuno I; Mohri N; Akamo Y; Terada J; Shibata T; Yamamoto T; Takeyama H; Manabe T; Yotsuyanagi T
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1512-5. PubMed ID: 8854793
[TBL] [Abstract][Full Text] [Related]
5. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
Fujiwara K; Yamauchi H; Sawada S; Koike H; Mohri H; Ohishi Y; Kohno I
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effect of liposome-entrapped carboplatin after intraperitoneal administration in rats].
Yasui T; Mizuno I; Ichino T; Akamo Y; Yamamoto T; Itabashi Y; Saito T; Kurahashi S; Tanimoto N; Yura J
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1753-5. PubMed ID: 1530349
[TBL] [Abstract][Full Text] [Related]
7. [Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumor and normal brain tissues].
Shinohara C; Matsumoto K; Kuriyama M; Adachi H; Ono Y; Higashi H; Furuta T; Ohmoto T
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1163-8. PubMed ID: 8031157
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
Guillet P; Monjanel S; Nicoara A; Duffaud F; Lacarelle B; Bagarry-Liegey D; Durand A; Catalin J; Favre R
Cancer Chemother Pharmacol; 1997; 40(2):143-9. PubMed ID: 9182836
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer].
Ohno M; Hirokawa M; Hando T
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2355-61. PubMed ID: 1463342
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
Lindnér P; Heath D; Howell S; Naredi P; Hafström L
Clin Cancer Res; 1996 Feb; 2(2):311-7. PubMed ID: 9816174
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of pelvic transarterial chemoembolization with lipiodol ultra-fluid carboplatin and transarterial carboplatin through experiment in dogs].
Chen CL; Sun MH; Tan DC; Liang LZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1405-8. PubMed ID: 15566645
[TBL] [Abstract][Full Text] [Related]
14. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients.
Oguri T; Isobe T; Mitsuta K; Masuda K; Daga H; Ishikawa N; Fujitaka K; Miyazaki M; Kohno N
Anticancer Res; 2001; 21(6A):3933-6. PubMed ID: 11911273
[TBL] [Abstract][Full Text] [Related]
16. [Possibility of alpha-tricalcium phosphate (alpha-TCP) particles as a drug carrier for treatment of abdominal carcinomatosis].
Ueda T; Mizuno I; Yotsuyanagi T; Akamo Y; Mohri N; Terada J; Shibata T; Yamamoto T; Takeyama H; Manabe T
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1789-93. PubMed ID: 9382534
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of intraperitoneal carboplatin administration-- pharmacokinetic analysis].
Ito K; Itani Y; Furuki K; Tamori N; Noda T; Adachi S; Hirano Y; Kato Y; Kiyozuka Y
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1180-6. PubMed ID: 1453047
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.
Bruzzone M; Rubagotti A; Gadducci A; Catsafados E; Foglia G; Brunetti I; Giannessi PG; Carnino F; Iskra L; Rosso R; Martoni A; Pannuti F; De Lisi V; Maltoni R; Ridolfi R; Mammoliti S; Gallo L; Boccardo F; Ragni N; Conte PF
Gynecol Oncol; 1997 Jun; 65(3):499-505. PubMed ID: 9190982
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
20. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
Los G; van Vugt MJ; Pinedo HM
Br J Cancer; 1994 Feb; 69(2):235-41. PubMed ID: 8297720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
